{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:21:49Z","timestamp":1787066509398,"version":"build-2736575974"},"reference-count":36,"publisher":"Georg Thieme Verlag KG","issue":"02","license":[{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bristol Myers Squibb and Janssen Research & Development, LLC"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TH Open"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:p>Background\u2003Factor XIa (FXIa) is an emerging therapeutic target, and FXIa inhibition is a promising mechanism to improve therapeutic index over current anticoagulants. Milvexian (BMS-986177\/JNJ-70033093) is an oral small-molecule FXIa inhibitor.<\/jats:p>\n                  <jats:p>Objective\u2003Milvexian's antithrombotic efficacy was characterized in a rabbit arteriovenous (AV) shunt model of venous thrombosis and compared with the factor Xa inhibitor apixaban and the direct thrombin inhibitor dabigatran.<\/jats:p>\n                  <jats:p>Methods\u2003The AV shunt model of thrombosis was conducted in anesthetized rabbits. Vehicle or drugs were administered as intravenous bolus plus a continuous infusion. Thrombus weight was the primary efficacy endpoint. Ex vivo activated partial thromboplastin time (aPTT), prothrombin time (PT), and thrombin time (TT) were measured as the pharmacodynamic responses.<\/jats:p>\n                  <jats:p>Results\u2003Milvexian dose dependently reduced thrombus weights by 34.3\u2009\u00b1\u20097.9, 51.6\u2009\u00b1\u20096.8 (p\u2009&lt;\u20090.01; n\u2009=\u20095), and 66.9\u2009\u00b1\u20094.8% (p\u2009&lt;\u20090.001; n\u2009=\u20096) versus vehicle at 0.25\u2009+\u20090.17, 1.0\u2009+\u20090.67, and 4.0\u2009\u00b1\u20092.68\u2009mg\/kg bolus\u2009+\u2009mg\/kg\/h infusion, respectively. Ex vivo clotting data supported a dose-dependent prolongation of aPTT (with 1.54-, 2.23-, and 3.12-fold increases from baseline upon the AV shunt start), but no changes in PT and TT. Dose-dependent inhibition in thrombus weight and clotting assays was also demonstrated for both apixaban and dabigatran as the references for the model validation.<\/jats:p>\n                  <jats:p>Conclusion\u2003Results demonstrate that milvexian is an effective anticoagulant for prevention of venous thrombosis in the rabbit model, which supports the utility of milvexian in venous thrombosis, as seen in the phase 2 clinical study.<\/jats:p>","DOI":"10.1055\/a-2061-3311","type":"journal-article","created":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T19:43:27Z","timestamp":1679600607000},"page":"e97-e104","source":"Crossref","is-referenced-by-count":7,"title":["Antithrombotic Effects of the Novel Small-Molecule Factor XIa Inhibitor Milvexian in a Rabbit Arteriovenous Shunt Model of Venous Thrombosis"],"prefix":"10.1055","volume":"07","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7780-4494","authenticated-orcid":false,"given":"Xinkang","family":"Wang","sequence":"additional","affiliation":[{"name":"Cardiovascular & Metabolism Therapeutic Area, Janssen Research & Development, LLC, Spring House, Pennsylvania, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu","family":"Li","sequence":"additional","affiliation":[{"name":"Cardiovascular & Metabolism Therapeutic Area, Janssen Research & Development, LLC, Spring House, Pennsylvania, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuyong","family":"Du","sequence":"additional","affiliation":[{"name":"Cardiovascular & Metabolism Therapeutic Area, Janssen Research & Development, LLC, Spring House, Pennsylvania, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neetu","family":"Shukla","sequence":"additional","affiliation":[{"name":"Formulation, Janssen Research & Development, LLC, Spring House, Pennsylvania, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea R.","family":"Nawrocki","sequence":"additional","affiliation":[{"name":"Cardiovascular & Metabolism Therapeutic Area, Janssen Research & Development, LLC, Spring House, Pennsylvania, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhu","family":"Chintala","sequence":"additional","affiliation":[{"name":"Cardiovascular & Metabolism Therapeutic Area, Janssen Research & Development, LLC, Spring House, Pennsylvania, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2023,4,24]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(18)32203-7","article-title":"Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"GBD 2017 Causes of Death Collaborators","year":"2018","journal-title":"Lancet"},{"issue":"11","key":"ref2","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.amjmed.2016.05.041","article-title":"Evaluation of dose-reduced direct oral anticoagulant therapy","volume":"129","author":"M E Barra","year":"2016","journal-title":"Am J Med"},{"issue":"08","key":"ref3","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/jth.13005","article-title":"Factor XI and contact activation as targets for antithrombotic therapy","volume":"13","author":"D Gailani","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref4","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1517\/13543776.2016.1154045","article-title":"Factor XIa inhibitors: a review of the patent literature","volume":"26","author":"R A Al-Horani","year":"2016","journal-title":"Expert Opin Ther Pat"},{"issue":"03","key":"ref5","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1161\/ATVBAHA.118.312130","article-title":"Intrinsic pathway of coagulation and thrombosis","volume":"39","author":"S P Grover","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"02","key":"ref6","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1160\/TH10-05-0307","article-title":"Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis","volume":"105","author":"O Salomon","year":"2011","journal-title":"Thromb Haemost"},{"issue":"09","key":"ref7","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1182\/blood-2016-09-742262","article-title":"Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events","volume":"129","author":"M Preis","year":"2017","journal-title":"Blood"},{"issue":"10","key":"ref8","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1056\/NEJM200003093421004","article-title":"High levels of coagulation factor XI as a risk factor for venous thrombosis","volume":"342","author":"J C Meijers","year":"2000","journal-title":"N Engl J Med"},{"issue":"03","key":"ref9","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1309\/QC259F09UNMKVP0R","article-title":"Elevated factor XI activity levels are associated with an increased odds ratio for cerebrovascular events","volume":"126","author":"D T Yang","year":"2006","journal-title":"Am J Clin Pathol"},{"issue":"03","key":"ref10","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"H R B\u00fcller","year":"2015","journal-title":"N Engl J Med"},{"issue":"07","key":"ref11","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"P Verhamme","year":"2021","journal-title":"N Engl J Med"},{"issue":"02","key":"ref12","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2019.20687","article-title":"Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial","volume":"323","author":"J I Weitz","year":"2020","journal-title":"JAMA"},{"issue":"04","key":"ref13","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1055\/s-0037-1613081","article-title":"FXI is essential for thrombus formation following FeCl3-induced injury of the carotid artery in the mouse","volume":"87","author":"E D Rosen","year":"2002","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref14","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1538-7836.2005.01236.x","article-title":"Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice","volume":"3","author":"X Wang","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"09","key":"ref15","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1111\/j.1538-7836.2006.02093.x","article-title":"Effects of factor XI deficiency on ferric chloride-induced vena cava thrombosis in mice","volume":"4","author":"X Wang","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref16","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/00001721-199703000-00008","article-title":"A murine model of factor XI deficiency","volume":"8","author":"D Gailani","year":"1997","journal-title":"Blood Coagul Fibrinolysis"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ejphar.2007.05.043","article-title":"Antithrombotic and hemostatic effects of a small molecule factor XIa inhibitor in rats","volume":"570","author":"W A Schumacher","year":"2007","journal-title":"Eur J Pharmacol"},{"issue":"07","key":"ref18","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1111\/j.1538-7836.2006.01973.x","article-title":"Factor XI contributes to thrombus propagation on injured neointima of the rabbit iliac artery","volume":"4","author":"A Yamashita","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref19","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s11239-015-1258-7","article-title":"In vitro, antithrombotic and bleeding time studies of BMS-654457, a small-molecule, reversible and direct inhibitor of factor XIa","volume":"40","author":"P C Wong","year":"2015","journal-title":"J Thromb Thrombolysis"},{"issue":"03","key":"ref20","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1182\/blood-2003-01-0324","article-title":"Factor XI-dependence of surface- and tissue factor-initiated thrombus propagation in primates","volume":"102","author":"A Gruber","year":"2003","journal-title":"Blood"},{"issue":"04","key":"ref21","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood-2008-06-163675","article-title":"Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI","volume":"113","author":"E I Tucker","year":"2009","journal-title":"Blood"},{"issue":"03","key":"ref22","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1021\/acs.jmedchem.1c00613","article-title":"Discovery of milvexian, a high-affinity, orally bioavailable inhibitor of factor XIa in clinical studies for antithrombotic therapy","volume":"65","author":"A K Dilger","year":"2022","journal-title":"J Med Chem"},{"issue":"23","key":"ref23","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism","volume":"385","author":"J I Weitz","year":"2021","journal-title":"N Engl J Med"},{"issue":"02","key":"ref24","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/jth.15588","article-title":"Milvexian, an orally bioavailable, small-molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits","volume":"20","author":"P C Wong","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref25","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1538-7836.2008.02939.x","article-title":"Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies","volume":"6","author":"P C Wong","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref26","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.thromres.2014.07.003","article-title":"Thrombotic safety of prothrombin complex concentrate (Beriplex P\/N) for dabigatran reversal in a rabbit model","volume":"134","author":"E Herzog","year":"2014","journal-title":"Thromb Res"},{"issue":"01","key":"ref27","first-page":"351","article-title":"Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics","volume":"292","author":"P C Wong","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"ref28","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1111\/j.1538-7836.2008.03092.x","article-title":"Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits","volume":"6","author":"P C Wong","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"08","key":"ref29","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/j.1538-7836.2009.03503.x","article-title":"Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits","volume":"7","author":"P C Wong","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref30","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.3390\/ijms24032569","article-title":"Thrombosis models: an overview of common in vivo and in vitro models of thrombosis","volume":"24","author":"S Ayyoub","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"09","key":"ref31","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1161\/ATVBAHA.120.315754","article-title":"Thrombus structural composition in cardiovascular disease","volume":"41","author":"G Alkarithi","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"04","key":"ref32","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s11239-011-0551-3","article-title":"Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor","volume":"31","author":"P C Wong","year":"2011","journal-title":"J Thromb Thrombolysis"},{"issue":"06","key":"ref33","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/j.1538-7836.2007.02526.x","article-title":"Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis","volume":"5","author":"W Wienen","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref34","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/jth.15700","article-title":"Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa","volume":"20","author":"S Heitmeier","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"11","key":"ref35","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.3748\/wjg.v23.i11.1954","article-title":"Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management","volume":"23","author":"K S Cheung","year":"2017","journal-title":"World J Gastroenterol"},{"issue":"09","key":"ref36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta21090","article-title":"Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis","volume":"21","author":"J A Sterne","year":"2017","journal-title":"Health Technol Assess"}],"container-title":["TH Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2061-3311.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T20:20:46Z","timestamp":1682367646000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2061-3311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,23]]},"references-count":36,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2023,4,20]]},"published-print":{"date-parts":[[2023,4]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2061-3311","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2512-9465"],"issn-type":[{"value":"2512-9465","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3,23]]},"published":{"date-parts":[[2023,3,23]]}}}